BioCardia, Inc. announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.655 USD | -10.48% | -9.06% | -52.62% |
May. 21 | BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours | MT |
May. 14 | Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024 |
1st Jan change | Capi. | |
---|---|---|
-52.62% | 9.31M | |
+10.36% | 114B | |
+10.91% | 105B | |
-5.45% | 23.83B | |
-0.32% | 21.73B | |
-10.12% | 18.1B | |
-42.36% | 16.34B | |
-16.36% | 16.13B | |
+1.38% | 13.75B | |
+31.83% | 11.76B |
- Stock Market
- Equities
- BCDA Stock
- News BioCardia, Inc.
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort